The next-generation antisense oligonucleotide AZD9150, which targets the 3’ untranslated region of STAT3 to inhibit STAT3 protein, has demonstrated early clinical activity in lung cancer and lymphoma, with deceases in circulating tumor cells and MDSCs along with increases in CD8+ T cells reported in the latter [213]. The gene discussed is STAT3; the disease is lung carcinoma.